JEANNE BOLGER

Dr. Jeanne Bolger stands as a pivotal figure in the European life sciences venture capital landscape, serving as a highly respected Venture Partner at Seroba Life Sciences. Seroba Life Sciences is renowned for its strategic investments in innovative European life science companies, and Dr. Bolger's expertise is instrumental in driving this mission forward. Her role involves identifying groundbreaking early-stage and growth-stage companies with the potential to revolutionize healthcare, guiding them through critical development phases, and ultimately bringing novel therapies and technologies to patients.

Jeanne's investment focus at Seroba Life Sciences spans a broad spectrum of the life sciences sector. She is particularly interested in companies developing cutting-edge solutions in biotechnology, pharmaceuticals, and medical technology. Her deep understanding of drug discovery, clinical development pathways, and regulatory landscapes allows her to evaluate opportunities with a discerning eye, ensuring that Seroba invests in ventures with robust scientific foundations and clear market potential. She also actively supports portfolio companies in navigating complex clinical trials, securing regulatory approvals, and formulating effective commercialization strategies.

Dr. Bolger's impressive career background provides a unique blend of medical insight and extensive industry experience. A qualified medical doctor, she brings a patient-centric perspective to her investment decisions. Prior to joining Seroba Life Sciences, Jeanne held senior leadership positions at several global pharmaceutical giants, including Pfizer, Amgen, and GSK. Notably, she also served as Vice President of New Business Development at Johnson & Johnson Innovation, where she was responsible for forging strategic partnerships and identifying disruptive technologies. This rich history in both clinical practice and corporate innovation equips her with an unparalleled ability to assess scientific merit, market viability, and operational challenges faced by life science startups.

Throughout her tenure, Dr. Bolger has been actively involved in shaping the trajectory of numerous promising companies. While specific investment details are often proprietary, her contributions are evident through her board positions at various Seroba portfolio companies, such as Inotrem, Complement Therapeutics, and Adcendo. In these roles, she provides invaluable strategic oversight, helping companies refine their scientific strategies, accelerate clinical programs, and prepare for successful market entry. Her guidance is crucial in transforming innovative research into tangible healthcare solutions, solidifying her reputation as a key enabler of progress in the life sciences investment community.